2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Liver Failure
1
Leukemia-Lymphoma, Adult T-Cell
1
Hepatitis C
1
Hepatitis B
1
Hepatic Insufficiency
1
Head and Neck Neoplasms
1
HIV Infections
1
Carcinoma, Hepatocellular
1
Interventions
entecavir
10
Lamivudine
5
Tenofovir
4
lenvatinib
2
Sorafenib
2
Radiofrequency Ablation
2
Hepatitis B Vaccines
2
tenofovir alafenamide
1
polysaccharide MGN3
1
peginterferon alfa-2b
1
peginterferon alfa-2a
1
navitoclax
1
menatetrenone
1
lens intermediate filament proteins
1
human papillomavirus vaccine, L1 type 16, 18
1
hepatitis B hyperimmune globulin
1
bicyclol
1
adefovir dipivoxil
1
adefovir
1
Urinalysis
1
Ultrasonography
1
Tumor Necrosis Factor-alpha
1
Tetanus Toxoid
1
Telbivudine
1
Tablets
1
Standard of Care
1
Rapid Diagnostic Tests
1
Raltegravir Potassium
1
Radiomics
1
Practice Guidelines as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hepatitis B
×
Raltegravir Potassium
×
Clear all
NCT01022476
2026-04-06
LIVERAL
ANRS, Emerging Infectious Diseases
Phase 1/2
Completed
14 enrolled